Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$155.04 USD

155.04
7,145,777

-0.43 (-0.28%)

Updated Nov 11, 2024 04:00 PM ET

After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Ethan Feller headshot

Momentum Mondays: Stocks Setting up for an Epic Dip Buying Opportunity?

by Ethan Feller

Want to start the week ahead of the pack? Check out Momentum Mondays!

Kinjel Shah headshot

5 Large Drug Stocks to Watch as New Drug Approvals & M&A Gain Pace

by Kinjel Shah

Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Novartis (NVS) and AstraZeneca (AZN) are worth retaining in your portfolio.

Should Schwab U.S. Large-Cap Value ETF (SCHV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SCHV

Amphastar Pharma (AMPH) Stock Skyrockets 89% YTD: Here's Why

by Zacks Equity Research

Amphastar Pharma (AMPH) shares are up 89.1% year to date due to the acquisition of Baqsimi from Lilly. The company also receives FDA approval for Naloxone.

Here's Why You Should Add Dr. Reddy's (RDY) to Your Portfolio

by Zacks Equity Research

Dr. Reddy's (RDY) continues to enjoy a strong foothold in the global generics market due to its deep generic drugs pipeline. The company is also looking to strengthen its biosimilars portfolio.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Okays PFE & JNJ Drugs, EU Approves ABBV's Migraine Drug

by Kinjel Shah

FDA approves Pfizer's (PFE) Elrexfio (elranatamab) for RRMM and J&J's (JNJ) oral combination tablet, Akeega to treat BRCA-positive mCRPC. European Commission approves AbbVie's (ABBV) Aquipta for migraine.

Here's Why it is a Good Time to Buy J&J's (JNJ) Stock Now

by Zacks Equity Research

J&J's (JNJ) Pharma sales are being driven by key drugs like Darzalex and new products. J&J's Pharma and MedTech units are likely to continue to drive sales growth in 2023.

AbbVie (ABBV) Gets EU Approval for Migraine Prevention Drug

by Zacks Equity Research

Following the approval, AbbVie's (ABBV) Aquipta is the first and the only oral CGRP receptor antagonist approved in the EU to prevent episodic and chronic migraines.

Eli Lilly (LLY) Stock Up Almost 50% Year to Date: Here's Why

by Zacks Equity Research

Sales of Lilly's (LLY) new drug, Mounjaro are already benefiting from strong demand trends. Lilly expects regulatory decisions for some key pipeline candidates this year, which are key to growth.

Seagen's (SGEN) Breast Cancer Study on Tuksya Combo Meets Goal

by Zacks Equity Research

Seagen (SGEN) announces positive top-line results from its breast cancer study evaluating Tuksya in combination with Roche's Kadcyla.

Kodiak (KOD) Q2 Earnings Miss, New Lead Candidate in Focus

by Zacks Equity Research

Kodiak (KOD) reports weaker-than-expected results in second-quarter 2023. The company also provides an update on the status of its pipeline after discontinuing the tarcocimab program.

Pfizer's (PFE) New Multiple Myeloma Drug Elrexfio Gets FDA Nod

by Zacks Equity Research

The FDA's accelerated approval of Pfizer's (PFE) new multiple myeloma drug Elrexfio/elranatamab is based on data from the pivotal phase II MagnetisMM-3 study.

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Is iShares Core Dividend Growth ETF (DGRO) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DGRO

Boston Scientific's (BSX) POLARx System Gets FDA Approval

by Zacks Equity Research

Boston Scientific's (BSX) POLARx enables doctors to expand and modify the new POLARx catheter to match a patient's unique anatomy during an ablation treatment.

Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%

by Zacks Equity Research

Atreca (BCEL) suspends the development of only pipeline candidate, ATRC-101, in clinical evaluation, as part of its business restructuring efforts and cuts headcount by 40%. The stock falls 37%.

Sweta Killa headshot

Pharma ETFs in Focus Post Q2 Earnings

by Sweta Killa

Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.

Johnson & Johnson (JNJ) Could Be a Great Choice

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

Catalyst (CPRX) Q2 Earnings & Sales Top, 2023 Outlook Raised

by Zacks Equity Research

Catalyst (CPRX) reports better-than-expected second-quarter 2023 results. Management raises full-year 2023 guidance.

Kinjel Shah headshot

Pharma Stock Roundup: LLY, BAYRY Post Q2 Results, NVO's Wegovy Cuts Heart Attack Risk

by Kinjel Shah

Eli Lilly (LLY), Bayer (BAYRY) and Novo Nordisk (NVO) announce second-quarter results.

Novo Nordisk (NVO) Q2 Earnings and Sales Miss, 2023 View Up

by Zacks Equity Research

Novo Nordisk (NVO) reports weaker-than-expected second-quarter 2023 results, missing both earnings and sales estimates. Management, however, raises 2023 guidance.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

by Zacks Equity Research

Sector ETF report for FHLC

Is Vanguard High Dividend Yield ETF (VYM) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for VYM

Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for HDV